美登素 - Suppr | 超能文献

Suppr

超能文献

Maytansine.

作者信息

Issell B F, Crooke S T

出版信息

Cancer Treat Rev. 1978 Dec;5(4):199-207. doi: 10.1016/s0305-7372(78)80014-0.

DOI:10.1016/s0305-7372(78)80014-0

PMID:367597

Abstract

摘要

相似文献

Maytansine.美登素

Cancer Treat Rev. 1978 Dec;5(4):199-207. doi: 10.1016/s0305-7372(78)80014-0.

Stathmokinetic and therapeutic effects of maytansine in mice bearing P388 and L1210 leukemias.美登素对携带P388和L1210白血病的小鼠的细胞分裂抑制及治疗作用。

Biochem Pharmacol. 1978;27(15):1973-5. doi: 10.1016/0006-2952(78)90014-x.

Experimental studies with maytansine--a new antitumor agent.美登素——一种新型抗肿瘤药物的实验研究。

Bibl Haematol. 1975 Oct(43):495-500. doi: 10.1159/000399202.

Phase I study of weekly maytansine given by iv bolus or 24-hour infusion.

Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1953-60.

A therapeutic trial of maytansine.

Cancer Clin Trials. 1978 Summer;1(2):113-7.

Phase II evaluation of maytansine in patients with advanced head and neck cancer.

Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2061-2.

Flow microfluorometric analysis of P388 murine leukemia after administration of vincristine and maytansine in vivo.体内给予长春新碱和美登素后P388小鼠白血病的流式微量荧光分析。

J Natl Cancer Inst. 1978 Mar;60(3):649-52. doi: 10.1093/jnci/60.3.649.

Pharmacology of antitumor agents from higher plants.高等植物抗肿瘤药物的药理学

Cancer Treat Rep. 1976 Aug;60(8):1127-39.

Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study.

Cancer Treat Rep. 1982 Jul;66(7):1687-8.

Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids.天然和半合成美登素类化合物中抗白血病活性的结构要求。

J Med Chem. 1978 Jan;21(1):31-7. doi: 10.1021/jm00199a006.

引用本文的文献

A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas.一项高内涵克隆形成存活药物筛选确定美登素为脑膜瘤的一种有效放射增敏剂。

Front Immunol. 2025 Mar 18;16:1557165. doi: 10.3389/fimmu.2025.1557165. eCollection 2025.

Advances in the study of marketed antibody-drug Conjugates (ADCs) for the treatment of breast cancer.用于治疗乳腺癌的上市抗体药物偶联物（ADC）的研究进展

Front Pharmacol. 2024 Jan 30;14:1332539. doi: 10.3389/fphar.2023.1332539. eCollection 2023.

Systemic Therapies for HER2-Positive Advanced Breast Cancer.HER2阳性晚期乳腺癌的全身治疗

Cancers (Basel). 2023 Dec 20;16(1):23. doi: 10.3390/cancers16010023.

Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates.利用有效载药结合选择性增强剂提高美登素类抗体药物偶联物的治疗指数。

Mol Cancer Ther. 2023 Nov 1;22(11):1332-1342. doi: 10.1158/1535-7163.MCT-22-0804.

Mechanisms of Resistance to Antibody-Drug Conjugates.抗体药物偶联物耐药机制。

Int J Mol Sci. 2023 Jun 2;24(11):9674. doi: 10.3390/ijms24119674.

Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers.ado曲妥珠单抗（ado-tratuzumab emtansine）在乳腺癌之外：靶向其他HER2阳性癌症的治疗作用

Front Mol Biosci. 2023 May 11;10:1165781. doi: 10.3389/fmolb.2023.1165781. eCollection 2023.

Advances and Prospects of Prolamine Corn Protein Zein as Promising Multifunctional Drug Delivery System for Cancer Treatment.醇溶蛋白玉米蛋白玉米醇溶蛋白作为有前途的多功能药物输送系统在癌症治疗中的进展和前景。

Int J Nanomedicine. 2023 May 15;18:2589-2621. doi: 10.2147/IJN.S402891. eCollection 2023.

Implementation of Systematic Bioanalysis of Antibody-Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats.用于大鼠体内ado曲妥珠单抗（T-DM1）临床前药代动力学研究的抗体-药物偶联物系统生物分析的实施。

Pharmaceutics. 2023 Feb 24;15(3):756. doi: 10.3390/pharmaceutics15030756.

Increased yield of AP-3 by inactivation of asm25 in Actinosynnema pretiosum ssp. auranticum ATCC 31565.通过失活 Actinosynnema pretiosum ssp. auranticum ATCC 31565 中的 asm25，增加 AP-3 的产量。

PLoS One. 2022 Mar 22;17(3):e0265517. doi: 10.1371/journal.pone.0265517. eCollection 2022.

Maytansinol Derivatives: Side Reactions as a Chance for New Tubulin Binders.美登素醇衍生物：作为新型微管蛋白结合剂契机的副作用

Chemistry. 2022 Jan 10;28(2):e202103520. doi: 10.1002/chem.202103520. Epub 2021 Nov 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验